There was no association of IL-12/23 inhibitors (HR, 0.87; 95% CI, 0.66-1.16) or IL-17 inhibitors (HR, 1.03; 95% CI, 0.74-1.42) with risk of paradoxical eczema. The gene discussed is IL17A; the disease is Eczematoid dermatitis.